Migraine with Brainstem Aura Market Research Report – Forecast to 2030

Migraine with Brainstem Aura Market Research Report By Diagnosis (Magnetic Resonance Imaging, Other), by Treatment (Abortive Medication, Other), by Distribution Channel (Retail Pharmacies, Other), End-User (Hospitals & Clinics, Other)– Forecast Till 2030

ID: MRFR/Pharma/4944-HCR | 100 Pages | Author: Rahul Gotadki | February 2024         

Migraine with Brainstem Aura Market Scenario


Migraine with brainstem aura market is expected to grow USD 10.67 Billion at a CAGR 5.30% the forecast period 2023 to 2030. A migraine with brainstem aura is also known as a basilar migraine or basilar artery migraine. It is a rare type of a migraine that begins in the base of the brain (brain stem). A migraine with brainstem aura occurs in about 1.5% of the patients suffering from with a headache. This migraine can occur in men and women of all ages.


The symptoms of this migraine include visual disturbances in both eyes, vertigo, hearing problems, nausea, dizziness among others. A migraine with brainstem aura (MBA) may affect one or both the sides of the brain. This rare migraine may be caused by a constriction of blood vessels that limit the blood flow to the brain. Moreover, certain external factors such as stress, motion sickness, epilepsy, alcoholism, prolonged hunger, excessive use of headache medications can trigger basilar artery migraines.


The factors such as rising prevalence of a migraine and growing awareness about rare types of migraines in the developed economies are major drivers for the market growth. In addition, the rising need for better treatment approaches, increasing investment of biotechnology and pharmaceutical industries in research & development (R&D) are expected to contribute to the growth of the market. However, side effects associated with migraine treatment drugs may hamper the growth of the market during the forecast period.


Segmentation


The migraine with brainstem aura market has been segmented into diagnosis, treatment, distribution channel, and end-user.


The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), computerized tomography (CT), and others.


The market, on the basis of treatment, has been segmented into abortive medication and preventive medication. The abortive medication segment has been segmented into non-steroidal anti-inflammatory drugs (NSAIDs), anti-nausea medications, and others. The preventive medication segment has been further segmented into botox injections, antidepressants, and others.


On the basis of the distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies, and others.


The market, by end-user, has been segmented into hospital & clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The migraine with brainstem aura market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European migraine with brainstem aura market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The migraine with brainstem aura market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The migraine with brainstem aura market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Allergen Plc, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc, Impax Laboratories, Eli Lily and Company, and Johnson & Johnson are some of the key players in the global market.


Regional Market Summary


Migraine with Brainstem Aura Market Share (%), by Region, 2017


Migraine with Brainstem Aura Market Share


Source: Centers for Disease Control and Prevention (CDC), White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the migraine with brainstem aura market owing to a well-developed healthcare sector, rising prevalence of migraine and growing healthcare expenditure. According to the Centers for Disease Control and Prevention (CDC), in 2015, 20% of women and 9.7% of men aged 18 or more had a migraine. Additionally, the large number of research and development (R&D) activities contributes to the growth of the market.


Europe is expected to hold the second largest position in the migraine with brainstem aura. The market growth in this region is attributed to the availability of funds for research, growing prevalence of migraine, and increasing healthcare expenditure. According to the World Health Organization (WHO), it is estimated that around 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK.


The migraine with brainstem aura market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of migraine and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Migraine with Brainstem Aura Market, by Diagnosis



  • Magnetic Resonance Imaging (MRI)

  • Computerized Tomography (CT)

  • Others


Migraine with Brainstem Aura Market, by Treatment



  • Abortive Medication


    • Non-steroidal anti-inflammatory drugs (NSAIDS)

    • Ibuprofen

    • Others

    • Anti-nausea Medications




  • Preventive Medication


    • Botox Injections

    • Antidepressants

    • Others



Migraine with Brainstem Aura Market, by Distribution Channel



  • Retail Pharmacies

  • Hospital Pharmacies

  • Others


Migraine with Brainstem Aura Market, by End-User



  • Hospital & Clinics

  • Diagnostic Centers

  • Others


Migraine with Brainstem Aura Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa

Report Scope:

Report Attribute/Metric Details
  Market Size  USD10.67 Billion
  CAGR   5.30%
  Base Year   2022
  Forecast Period   2023-2030
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment, Diagnosis, Distribution Channel, End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Allergen Plc, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc, Impax Laboratories, Eli Lily and Company, and Johnson & Johnson are some of the key players in the global market.
  Key Market Opportunities  
  Key Market Drivers   Increasing investment of biotechnology and pharmaceutical industries in research & development 




Frequently Asked Questions (FAQ) :

Growing awareness regarding migraine would be the dominating factor for Migraine with Brainstem Aura Market growth.

Name segments related to a diagnosis that is a part of the Migraine with Brainstem Aura Market assessment. The segments of Migraine with Brainstem Aura Market are magnetic resonance imaging (MRI), computerized tomography (CT), and others.

Migraine with Brainstem Aura Market study includes abortive medication and preventive medication.

The study of Migraine with Brainstem Aura Market includes retail pharmacies, hospital pharmacies, and others.

The Americas would dominate global Migraine with Brainstem Aura Market study.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid